Propanc Biopharma Inc (PPCB) Stock Analysis
Verdict: AVOID
Pre-revenue preclinical biotech with $12k cash and severe dilution risk trades on speculative headlines — upside is limited by bankruptcy risk.
Investment score: 13/100
Analysis as of
Is Propanc Biopharma Inc stock worth reviewing? AI model thesis
The AI model rates PPCB as an AVOID due to severe cash depletion ($12,088), zero revenue, and extreme dilution risk.
7-factor investment score
- Valuation: 10/100 (weight 20%)
- Financial Health: 5/100 (weight 15%)
- Technical Momentum: 15/100 (weight 15%)
- Earnings Quality: 10/100 (weight 15%)
- Insider Sentiment: 30/100 (weight 10%)
- Analyst Consensus: 20/100 (weight 10%)
- Risk-Adjusted Return: 10/100 (weight 15%)
Propanc Biopharma Inc opportunities and risks
What speaks for PPCB
- Preclinical PRP pan-cancer pipeline proof-of-concept
What speaks against PPCB
- Imminent cash depletion and insolvency risk
Peers and competitors
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| PPCB | n/a | 0.0x | n/a | 0.0% | 0.0% | -133.7% |
| NEUP | n/a | n/a | n/a | 104.7% | 272.0% | 292.6% |
| Peer median | n/a | n/a | n/a | 104.7% | 272.0% | 292.6% |
Frequently asked questions about Propanc Biopharma Inc (PPCB)
Is PPCB stock a good investment?
The cached TradeMates AI model rates Propanc Biopharma Inc as AVOID with an investment score of 13/100. The AI model rates PPCB as an AVOID due to severe cash depletion ($12,088), zero revenue, and extreme dilution risk. This is algorithmic model output, not personal investment advice.
Is PPCB stock a buy?
The TradeMates model verdict for PPCB is AVOID with an investment score of 13/100. Treat this as a model signal to review, not a personal buy recommendation.